SAB Biotherapeutics (SABS) Change in Cash (2020 - 2026)

SAB Biotherapeutics has reported Change in Cash for 7 years, with the latest figure at $10.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 407.5% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (up 277.27% YoY), and the FY2025 full-year result was $1.6 million, up 103.37% from the prior year.
• Change in Cash for Q1 2026 stood at $10.0 million, up from -$18.9 million in the prior quarter.
• The five-year high for Change in Cash was $54.1 million in Q4 2023, with the low at -$42.5 million in Q1 2024.
• Historically, Change in Cash has averaged -$1.1 million across 5 years, with a median of -$3.3 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Cash jumped 706.3% — and 2025, when it plunged 6825.84%.
• SAB Biotherapeutics' Change in Cash stood at $6.7 million in 2022, then soared by 706.3% to $54.1 million in 2023, then slumped by 100.5% to -$273209.0 in 2024, then sank by 6825.84% to -$18.9 million in 2025, then soared by 152.94% to $10.0 million in 2026.
• The last three Change in Cash figures came in at $10.0 million (Q1 2026), -$18.9 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.